Caliway Biopharmaceuticals
Tracked across 1 events · 6 articles · First seen Sep 23, 2026 · Last active Sep 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Caliway Biopharmaceuticals announced on September 21, 2026, final statistical results from its randomized, single-blind, placebo-controlled Phase 2 clinical trial CBL-0202DD evaluating CBL-514 for the treatment of Dercum's Disease, a rare disorder characterized by painful lipomas.…
Impact: Caliway Biopharmaceuticals is the central entity, reporting positive Phase 2 results for CBL-514 in Dercum's Disease and outlining expansion into Lipedema. The results support its pipeline value and future partnership potential, though its shares traded modestly lower after the announcement.
Sep 23, 2026 · 6 articles
95
Caliway Biopharmaceuticals announced positive Phase 2 resultsCaliway CBL-514 Phase 2...
85
Caliway Biopharmaceuticals achieved primary endpointCaliway CBL-514 Phase 2...
60
Caliway Biopharmaceuticals plans Lipedema developmentCaliway CBL-514 Phase 2...
ERGEN INTELLIGENCE
Track Caliway Biopharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard